返回 
加入收藏
南京地区25家医院2012－2014年分子靶向抗肿瘤药应用分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 南京地区25家医院2012－2014年分子靶向抗肿瘤药应用分析 |
| TITLE： | |
| 摘要： | 目的：为分子靶向抗肿瘤药的临床合理使用提供参考。方法：采用回顾性调查方法，对南京地区25家医院2012－2014年分子靶向抗肿瘤药的销售金额、用药频度（DDDs）、日均费用（DDC）及排序比（B/A）进行分析。结果：南京地区25家医院分子靶向抗肿瘤药销售金额由2012年的6 169.29万元增加至2013年的8 813.38万元，增长了42.86％，2014年下降至8 082.23万元，降低了8.3％。其中，单分子抗体药的销售金额构成比逐年下降，小分子酪氨酸激酶抑制剂的销售金额构成比逐年增长。利妥昔单抗、曲妥珠单抗各年度销售金额均排名前列。曲妥珠单抗、吉非替尼和厄洛替尼连续3年DDDs排名前3，利用频度较高。大部分药物DDC相对稳定，B/A≥1，销售金额与用药频度同步性总体较好。结论：南京地区分子靶向抗肿瘤药的临床应用合理，价格因素对该类药物的应用影响较大。 |
| ABSTRACT： | OBJECTIVE： To provide reference for rational use of molecular targeted anti-tumor drugs in the clinic. METHODS： In retrospective survey， the utilization of molecular targeted anti-tumor drugs were statistically analyzed in 25 hospitals from Nanjing area during 2012-2014 in terms of consumption sum， DDDs， DDC and B/A. RESULTS： The consumption sum of molecular targeted anti-tumor drugs increased from 6 169.29 ten thousand yuan in 2012 to 8 813.38 ten thousand yuan， increasing by 42.86％； and then decreased to 8 082.3 ten thousand yuan， decreasing by 8.3％. The consumption sum ratio of single-molecule antibody agent decreased year by year， while that of small-molecule tyrosine kinase inhibitor increased year by year. Rituximab and trastuzumab took up the front in the list of annual consumption sum. Trastuzumab， gefitinib and erlotinib remained the top 3 places in the list of DDDs and were used frequently. DDC of most of molecular targeted anti-tumor drugs kept stable relatively， and the B/A value were more than 1； their consumption sum was well synchronized with DDDs. CONCLUSIONS： The utilization of molecular targeted anti-tumor drugs is reasonable in Nanjing area. The price of drugs greatly influence their utilization. |
| 期刊： | 2016年第27卷第14期 |
| 作者： | 王羽，刘慧，戴惠珍 |
| AUTHORS： | WANG Yu，LIU Hui，DAI Huizhen |
| 关键字： | 分子靶向药物；抗肿瘤药；销售金额；用药频度；应用分析；南京地区 |
| KEYWORDS： | Molecular targeted drugs； Anti-tumor drugs； Consumpiton sum； DDDs； Analysis of drug utilization； Nanjing area |
| 阅读数： | 341 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
